Therapeutic Hypothesis Testing With Rodent Brain Tumor Models

Derek A. Wainwright, Craig M. Horbinski, Rintaro Hashizume, C. David James*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


The development and application of rodent models for preclinical testing of novel therapeutics and approaches for treating brain tumors has been a mainstay of neuro-oncology preclinical research for decades, and is likely to remain so into the foreseeable future. These models serve as an important point of entry for analyzing the potential efficacy of experimental therapies that are being considered for clinical trial evaluation. Although rodent brain tumor models have seen substantial change, particularly since the introduction of genetically engineered mouse models, certain principles associated with the use of these models for therapeutic testing are enduring, and form the basis for this review. Here we discuss the most common rodent brain tumor models while directing specific attention to their usefulness in preclinical evaluation of experimental therapies. These models include genetically engineered mice that spontaneously or inducibly develop brain tumors; syngeneic rodent models in which cultured tumor cells are engrafted into the same strain of rodent from which they were derived; and patient-derived xenograft models in which human tumor cells are engrafted in immunocompromised rodents. The emphasis of this review is directed to the latter.

Original languageEnglish (US)
Pages (from-to)385-392
Number of pages8
Issue number2
StatePublished - Apr 1 2017


  • Immunocompetent vs. immunocompromised
  • Spontaneous vs. engraftment
  • Syngeneic
  • Xenograft

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Therapeutic Hypothesis Testing With Rodent Brain Tumor Models'. Together they form a unique fingerprint.

Cite this